Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax Inc (NQ: NVAX )

5.545 +0.085 (+1.56%)
Streaming Delayed Price Updated: 10:48 AM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax Inc

< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
What's Going On With Novavax Stock Tuesday?
Novavax Inc (NASDAQ: NVAX) shares are trading higher Tuesday. 
Via Benzinga
Could a Short Squeeze Be Coming for These 3 Heavily Shorted Stocks?
Should investors expect any of these stocks to turn their fortunes around next year? 
Via The Motley Fool
Where Will Novavax Be in 3 Years?
Novavax shares have plunged from early pandemic highs. 
Via The Motley Fool
Novavax Prepares Further Cost Cuts To Better Align With Demand-Challenged COVID-19 Vaccine Market
Novavax Inc (NASDAQ: NVAX) reported Q3 revenue of $187 million, compared to $735 million in the same period in 2022, beating the  
Via Benzinga
Exposures COVID-19
Wall Street To Snap Longest Winning Streak Since 2021 Today? Earnings, Bond Yields In Focus Ahead Of Powell's Speech
The stock market’s momentum appears to be waning, and futures suggest a mixed opening for Thursday. Earnings reports have generally been positive, with companies like Walt Disney Co. 
Via Benzinga
Novavax's Earnings: A Preview
Via Benzinga
The Fall Vaccination Season Is Here. Is Novavax a Buy?
Novavax shares have declined 28% this year. 
Via The Motley Fool
Down 75% From Its High, Has Novavax Stock Become Too Cheap to Pass Up?
It won't be easy for this company to win back investors, as the business faces some big challenges. 
Via The Motley Fool
Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares
The company issued below-consensus sales views for 2023 and 2024. 
Via Investor's Business Daily
7 Dangerous Stocks to Avoid No Matter What
Despite arguments to the contrary, stay away from each of these seven stocks to avoid, as each carries substantial downside risk. 
Via InvestorPlace
Top 6 Nasdaq Short Squeeze Play Stocks
The following are some heavily shorted tech stocks that may be worth considering. 
Via Talk Markets
Pfizer Reportedly Hikes Paxlovid Price To $1,390 — More Than Double What The Government Paid
The transition to the commercial market is planned for 2024 and could bolster sales. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Do These 5 Words From Pfizer Mean Trouble for Novavax?
Coronavirus vaccine sales could represent recurrent annual revenue for Novavax and rivals. 
Via The Motley Fool
Exposures COVID-19
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. 
Via Benzinga
Bitcoin's ETF Approval Rumor, Pfizer Slashes Annual Outlook, Activist Shareholder Shakes Up News Corp's Status Quo: Today's Top Stories
Benzinga Bitcoin Spiked On False ETF Approval Rumor 
Via Benzinga
Topics ETFs
Moderna, BioNTech Lead Covid Sell-Off After Pfizer Slashes Its Outlook By $9 Billion
Pfizer cut about $9 billion from its sales expectations for Covid products this year. 
Via Investor's Business Daily
Exposures COVID-19
Novavax Faces Setback, European Authority Delays Decision On Variant-Tailored COVID-19 Vaccine
Novavax Inc (NASDAQ: NVAX) faces a setback as the European Medicines Agency (EMA) delays a decision on its variant-tailored COVID-19 vaccine.  
Via Benzinga
Exposures COVID-19
The 10 Most Shorted Stocks Include 3 Tesla Rivals, But Not TSLA
Some big 2023 winners are shorted heavily, including two AI plays. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
US Stocks On Track For A Strong Start To Week, Buoyed By Earnings Optimism: Analyst Flags 13-14% Upside As Bull Market Enters Its Second Year
US stocks appear on track to start higher on Monday as traders look ahead to the earnings season to serve as upside catalyst. 
Via Benzinga
BioNTech, Moderna And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Is Novavax Stock a Buy Now?
Is this company just a pandemic stock? 
Via The Motley Fool
Novavax (NVAX) Stock Slides Despite Vaccine Availability
Although Novavax’s non-mRNA vaccine being available broadly represents good news, NVAX stock suffered due to unfavorable timing. 
Via InvestorPlace
AZZ, VOXX International And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher Wednesday, with the Dow Jones gaining around 100 points. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in... 
Via Benzinga
The COVID Vaccine Market Is Changing Dramatically. Do Vaccine Stocks Still Make Good Investments?
Vaccine revenue may have slipped but could still represent billions of dollars for these companies. 
Via The Motley Fool
Exposures COVID-19
Timing Favors Novavax's Delayed Approval, Arrival Ahead of Peak COVID Vaccine Demand
Last week, Novavax Inc (NASDAQ: NVAX) received FDA authorization for its updated COVID-19 vaccine, targeting the omicron subvariant XBB.1.5 in  
Via Benzinga
Exposures COVID-19 Product Safety
3 Pharma Stocks to Dump Before the Damage Is Done
There's never a shortage of pharma stocks to sell due to the nature of the sector, especially when compounded by current fears. 
Via InvestorPlace
This Could be Novavax's Big Opportunity
Novavax has lagged behind bigger rivals in the vaccine market. 
Via The Motley Fool
Did Moderna Just Jump Ahead of Rivals in a Potential Billion-Dollar Market?
Moderna, Pfizer, and Novavax all are working on combined vaccine candidates. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
51 52 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.